-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In 2021, many pharmaceutical companies have made major personnel adjustments, and the heads of major business departments of more than 30 pharmaceutical companies have left or transferred
.
In 2022, this situation will continue, and this week, the principals of many well-known pharmaceutical companies have "changed coaches" one after another
.
On April 1, CStone appointed Dr.
Zhou You as the general manager of the company's Greater China region and the head of the company's commercial department.
He was fully responsible for the commercialization of the company's products and reported directly to CStone's chairman and CEO, Dr.
Jiang Ningjun
.
Industry insiders believe that the appointment of the new executives may help CStone to seize the new opportunities of rapid changes in biopharmaceuticals, accelerate the business process, and further expand the precision treatment ecosystem
.
It is understood that before joining CStone, Zhou You served as Chief Marketing Officer of Sanofi Pasteur (China) and has performed well in many fields
.
For example, when he was in charge of the four pillars closely related to the vaccine business, he quickly improved the overall performance of the team in a short period of time, and delivered a number of innovative and influential projects
.
On March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer
.
After taking office, Wu Kun will be based in Shanghai, China and will report to Luo Wanli, CEO of Keixing
.
In this role, Kun Wu will be responsible for developing the commercialization strategy of Keixing and building a marketing excellence team to drive the commercialization of the company's growing product portfolio
.
It is understood that Mr.
Wu Kun has more than 20 years of experience in the pharmaceutical industry
.
Before joining Keixing, he served as Chief Operating Officer of Pfizer Biopharmaceutical Group China, leading a team of 5,000 people comprising sales, marketing, key accounts, commercial and business operations functions
.
In addition, he has led the team to achieve outstanding performance and successfully commercialized a number of blockbuster products
.
On March 31, Weili Medical also issued an announcement.
The board of directors of the company recently received a written resignation report from Huang An, the company's deputy general manager.
Huang An applied for his resignation as the company's deputy general manager due to work adjustment reasons
.
However, after resigning as the company's deputy general manager, he will hold a management position in the company's holding subsidiary Guangzhou Weili Jianyi Medical Equipment Co.
,
Ltd.
On March 29, Hainan Haiyao issued an announcement showing that the board of directors received a written resignation application report from the chairman of the company, Mr.
Pan Dazhong, on the 26th.
Mr.
Pan Dazhong was originally scheduled to serve until March 24, 2023, and is now applying for resignation as a director of the company due to retirement reasons.
, Chairman of the Board, Convenor of the Strategy Committee of the Board of Directors and Member of the Nomination Committee
.
It is worth noting that it has only been about a year since Pan Dazhong officially took over as chairman of Hainan Haiyao
.
In addition to Mr.
Pan Dazhong, since 2021, more than 10 senior executives of Hainan Haiyao have resigned from their corresponding management positions, including the positions of general manager, several deputy general managers and board secretary
.
On March 28, Pfizer announced that Chu Nan was the head of the digestive system/urology/hematological oncology field of the Oncology Division, and the appointment to report directly to Wang Yiqin, the general manager of the Oncology Division, came into effect
.
It is reported that he will be responsible for managing the sales and marketing teams of Pfizer China in the field of digestive system/urology/blood tumor therapy, formulating effective product and market strategies, developing and promoting the business development of product pipelines with strategic thinking, and better exploiting product potential to drive rapid business growth
.
In general, due to the changes in the pharmaceutical environment, both multinational pharmaceutical companies and local pharmaceutical companies are actively adapting to the changes and making corresponding business and personnel adjustments
.
This trend is also expected by industry insiders
.
It's just that it still takes time to verify whether a large number of pharmaceutical companies can meet expectations and promote the further development of the company after they have successively "changed coaches"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In 2022, this situation will continue, and this week, the principals of many well-known pharmaceutical companies have "changed coaches" one after another
.
On April 1, CStone appointed Dr.
Zhou You as the general manager of the company's Greater China region and the head of the company's commercial department.
He was fully responsible for the commercialization of the company's products and reported directly to CStone's chairman and CEO, Dr.
Jiang Ningjun
.
Industry insiders believe that the appointment of the new executives may help CStone to seize the new opportunities of rapid changes in biopharmaceuticals, accelerate the business process, and further expand the precision treatment ecosystem
.
It is understood that before joining CStone, Zhou You served as Chief Marketing Officer of Sanofi Pasteur (China) and has performed well in many fields
.
For example, when he was in charge of the four pillars closely related to the vaccine business, he quickly improved the overall performance of the team in a short period of time, and delivered a number of innovative and influential projects
.
On March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer
.
After taking office, Wu Kun will be based in Shanghai, China and will report to Luo Wanli, CEO of Keixing
.
In this role, Kun Wu will be responsible for developing the commercialization strategy of Keixing and building a marketing excellence team to drive the commercialization of the company's growing product portfolio
.
It is understood that Mr.
Wu Kun has more than 20 years of experience in the pharmaceutical industry
.
Before joining Keixing, he served as Chief Operating Officer of Pfizer Biopharmaceutical Group China, leading a team of 5,000 people comprising sales, marketing, key accounts, commercial and business operations functions
.
In addition, he has led the team to achieve outstanding performance and successfully commercialized a number of blockbuster products
.
On March 31, Weili Medical also issued an announcement.
The board of directors of the company recently received a written resignation report from Huang An, the company's deputy general manager.
Huang An applied for his resignation as the company's deputy general manager due to work adjustment reasons
.
However, after resigning as the company's deputy general manager, he will hold a management position in the company's holding subsidiary Guangzhou Weili Jianyi Medical Equipment Co.
,
Ltd.
On March 29, Hainan Haiyao issued an announcement showing that the board of directors received a written resignation application report from the chairman of the company, Mr.
Pan Dazhong, on the 26th.
Mr.
Pan Dazhong was originally scheduled to serve until March 24, 2023, and is now applying for resignation as a director of the company due to retirement reasons.
, Chairman of the Board, Convenor of the Strategy Committee of the Board of Directors and Member of the Nomination Committee
.
It is worth noting that it has only been about a year since Pan Dazhong officially took over as chairman of Hainan Haiyao
.
In addition to Mr.
Pan Dazhong, since 2021, more than 10 senior executives of Hainan Haiyao have resigned from their corresponding management positions, including the positions of general manager, several deputy general managers and board secretary
.
On March 28, Pfizer announced that Chu Nan was the head of the digestive system/urology/hematological oncology field of the Oncology Division, and the appointment to report directly to Wang Yiqin, the general manager of the Oncology Division, came into effect
.
It is reported that he will be responsible for managing the sales and marketing teams of Pfizer China in the field of digestive system/urology/blood tumor therapy, formulating effective product and market strategies, developing and promoting the business development of product pipelines with strategic thinking, and better exploiting product potential to drive rapid business growth
.
In general, due to the changes in the pharmaceutical environment, both multinational pharmaceutical companies and local pharmaceutical companies are actively adapting to the changes and making corresponding business and personnel adjustments
.
This trend is also expected by industry insiders
.
It's just that it still takes time to verify whether a large number of pharmaceutical companies can meet expectations and promote the further development of the company after they have successively "changed coaches"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
